BUCHANG PHARMA(SH:603858)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was RMB 3,514,950,369.96, representing a year-on-year increase of 9.83%[4] - The net profit attributable to shareholders was RMB 455,269,033.72, with a growth of 5.91% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 376,959,406.85, showing a significant increase of 34.80%[4] - Total revenue for Q1 2023 reached CNY 3,514,950,369.96, an increase of 9.79% compared to CNY 3,200,498,122.98 in Q1 2022[14] - Net profit for Q1 2023 was CNY 435,939,044.03, compared to CNY 410,806,616.97 in Q1 2022, indicating an increase of 6.09%[16] - Basic earnings per share for Q1 2023 were CNY 0.4116, compared to CNY 0.3886 in Q1 2022, reflecting an increase of 5.15%[16] Cash Flow - The net cash flow from operating activities was negative at RMB -87,014,604.71, a decline of 123.21% year-on-year[4] - In Q1 2023, the net cash flow from operating activities was -87,014,604.71, a significant decrease compared to 374,953,344.07 in Q1 2022[18] - Total cash inflow from operating activities was 3,411,358,272.84, down from 3,530,450,625.36 in the previous year, reflecting a decline of approximately 3.4%[18] - Cash outflow from operating activities increased to 3,498,372,877.55, compared to 3,155,497,281.29 in Q1 2022, marking an increase of about 10.9%[18] - The cash flow from operating activities showed a negative trend, indicating potential challenges in revenue generation and cost management[18] Assets and Liabilities - Total assets at the end of the reporting period were RMB 22,271,783,971.82, reflecting a 1.46% increase from the end of the previous year[5] - The company's total assets as of March 31, 2023, amounted to CNY 22,271,783,971.82, up from CNY 21,951,881,623.86 at the end of 2022[13] - Current assets totaled CNY 9,259,730,285.58, an increase of 2.97% from CNY 8,991,494,886.64 at the end of 2022[13] - The company's total liabilities decreased to CNY 9,531,548,863.51 from CNY 9,676,829,976.05, a reduction of 1.50%[13] - The company reported a decrease in contract liabilities to CNY 275,774,012.34 from CNY 376,521,161.31, a decline of 26.74%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 72,160[8] - The largest shareholder, Bichang (Hong Kong) Holdings Limited, holds 490,957,202 shares, accounting for 44.39% of the total shares[9] Government Subsidies and R&D - The company received government subsidies amounting to RMB 101,936,895.00, which are closely related to its normal business operations[6] - Research and development expenses for Q1 2023 were CNY 36,838,151.85, down from CNY 46,066,527.20 in Q1 2022, a decrease of 20.06%[16] Cash Flow from Investing and Financing Activities - The net cash flow from investing activities was -318,401,004.85, worsening from -146,993,360.40 in the same quarter last year[18] - Cash inflow from investing activities totaled 19,278,470.42, a significant increase from 5,193,438.24 in Q1 2022[18] - Cash outflow from financing activities was 675,587,797.54, down from 1,240,142,706.01 in Q1 2022, indicating a reduction of approximately 45.6%[18] - The net cash flow from financing activities was -134,225,310.34, slightly worse than -113,329,667.90 in the previous year[19] - The ending cash and cash equivalents balance was 1,581,662,776.52, an increase from 1,477,898,809.50 in Q1 2022[19] - The company reported a total cash inflow from financing activities of 541,362,487.20, down from 1,126,813,038.11 in the previous year[18]